Belgian Entertainment Stock News

Anheuser-Busch InBev (ENXTBR:ABI) opened 2026 with Q1 revenue of US$15.3b and basic EPS of US$1.30, setting a clear benchmark for how the rest of the year might shape up for the brewer’s top and bottom lines. The company has seen quarterly revenue move from US$13.6b in Q1 2025 to US$15.3b in Q1 2026, while basic EPS shifted from US$1.08 to US$1.30 over the same period. This gives you a clean read on how sales and per share earnings are tracking through the cycle. With that backdrop, the...

Earnings snapshot and why it matters now Cofinimmo (ENXTBR:COFB) has just reported first quarter 2026 results, with sales of €87.31 million compared with €86.81 million a year earlier, while net income came in at €53.51 million versus €64.26 million. This mix of slightly higher sales and lower profitability is giving investors fresh numbers to reassess the stock, especially following the recent share price moves over the past month and over the past three months. See our latest analysis for...

Executive and board reshuffle puts Umicore (ENXTBR:UMI) in focus Umicore (ENXTBR:UMI) has drawn fresh attention after shareholders approved new Supervisory Board appointments, while the company also named a new CFO and created a Chief Digital & Transformation Officer role. See our latest analysis for Umicore. The cluster of governance changes, dividend approval and BlackRock lifting its holding above 5% has coincided with a sharp pick up in momentum, with a 24.04% 1 month share price return...

Why Anheuser-Busch InBev (ENXTBR:ABI) is Back on Investor Radar Anheuser-Busch InBev (ENXTBR:ABI) has drawn attention after its recent share performance, with the stock showing positive returns over the past week, month and past 3 months alongside measurable annual revenue and net income. See our latest analysis for Anheuser-Busch InBev. The recent 1-day share price return of 9.34% builds on a 30-day share price return of 12.26% and a year to date share price return of 26.91%. The 1-year...

Investors may be wondering whether argenx at €678.60 is offering fair value or carrying a premium, particularly after its strong long term share price record. The stock has returned 2.0% over the last 7 days, 4.9% over the last 30 days, a 6.2% decline year to date and 19.8% over the last year, with longer term returns of 86.7% over 3 years and 220.1% over 5 years. Recent coverage around argenx has focused on its position in the biotech sector and investor debate around how much future growth...

What recent performance suggests about Azelis Group (ENXTBR:AZE) Azelis Group (ENXTBR:AZE) has drawn attention after a month return of 26.0%, contrasting with a 16.7% decline over the past year. This puts its recent share move in focus for investors. See our latest analysis for Azelis Group. The recent 26.0% 30 day share price return and 24.8% 90 day gain contrast with a 16.7% 1 year total shareholder return decline, suggesting short term momentum after a weaker longer period. If this kind of...

Dividend increase puts income focus on Financière de Tubize Financière de Tubize (ENXTBR:TUB) has approved a gross dividend of €1.08 per share at its 24 April 2026 general meeting, with payment scheduled from 11 May, ex-coupon on 7 May. See our latest analysis for Financière de Tubize. The dividend decision comes after a weaker 30 day share price return of a 10.84% decline and a 12.44% decline over 90 days. However, the 1 year total shareholder return of 46.48% and 3 year total shareholder...

Why Xior’s latest quarterly results matter for investors Xior Student Housing (ENXTBR:XIOR) has drawn fresh attention after reporting first quarter 2026 earnings, with sales of €48.67 million and net income of €48.6 million, compared with €43.88 million and €41.95 million a year earlier. See our latest analysis for Xior Student Housing. Despite the stronger first quarter figures, the share price is at €27.6, with a 1 day share price return of 0.91% but a 1 year total shareholder return of...

Sofina Société Anonyme (ENXTBR:SOF) has drawn investor attention after its recent share price moves, with a gain over the past month contrasting with weaker returns in the past 3 months and year. See our latest analysis for Sofina Société Anonyme. At the latest share price of €218.0, Sofina Société Anonyme's short term share price return has been slightly positive over the past month, while the year to date share price return and 1 year total shareholder return both remain negative,...

Umicore (ENXTBR:UMI) has appointed Lily Liu as Chief Financial Officer and Executive Vice President. The company is also creating a new Chief Digital & Transformation Officer role to focus on digitalization and operational excellence. These leadership changes reflect a shift in how Umicore organizes its executive team and oversees transformation initiatives. For investors watching ENXTBR:UMI, the leadership reshuffle comes with the stock at €17.18 and a mixed return profile. The share price...

Warehouses De Pauw (ENXTBR:WDP) drew fresh attention after reporting first quarter 2026 sales of €121.21 million and net income of €95.45 million, along with basic earnings per share of €0.41 from continuing operations. See our latest analysis for Warehouses De Pauw. The share price has softened recently, with a 1-day share price return of a 3.45% decline and a 90-day share price return of a 7.28% decline. At the same time, the 1-year total shareholder return of 5.36% and the 5-year total...

Why argenx is back in focus for investors argenx (ENXTBR:ARGX) is back on investors' radar after fresh analyst commentary highlighted expectations for its first quarter update, with particular attention on Vyvgart's prefilled syringe use in autoimmune conditions. That growing focus comes ahead of key regulatory milestones in ocular and seronegative myasthenia gravis. Upcoming decisions could influence how investors think about argenx's longer term growth runway and risk profile. See our...

Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Van de Velde...

NICE’s green light for UCB (ENXTBR:UCB) therapy Rystiggo for uncontrolled generalised myasthenia gravis on the NHS in England, plus the IMIDomics Patient Insight acquisition, has sharpened investor focus on the stock. See our latest analysis for UCB. The 1 day share price return of 2.21% takes UCB to €231.2, yet this comes after a 30 day share price return of negative 12.59%. This is even as the 1 year total shareholder return of 36.64% and 5 year total shareholder return of 211.86% point to...

ageas (ENXTBR:AGS) has drawn attention after its shares closed at €66.70, supported by a reported €9,429.0m in revenue and €1,712.0m in net income. This puts its insurance operations in clearer focus for investors. See our latest analysis for ageas. At a share price of €66.70, ageas has seen an 11.26% 90 day share price return and a 25.56% 1 year total shareholder return, which indicates momentum has been present over both shorter and longer periods. If this kind of steady compounding appeals...

At its 29 April 2026 shareholder meeting, Anheuser-Busch InBev approved a €1.15 gross total dividend for 2025 and refreshed its board, appointing Fabrizio Freda and Miguel Patricio as directors alongside new Restricted Share Directors. Coupled with a planned US$600.00 million investment in U.S. manufacturing and workforce training, these moves highlight AB InBev’s focus on strengthening operations and supporting shareholder returns. Next, we’ll examine how AB InBev’s newly approved...

Softimat S.A. ( EBR:SOFT ) just reported healthy earnings but the stock price didn't move much. Our analysis suggests...

Q1 2026 earnings snapshot and context Melexis (ENXTBR:MELE) opened Q1 2026 reporting season with recent quarterly numbers that put revenue and EPS in clear focus, with Q4 2025 revenue at €214.5 million and basic EPS at €0.56 helping anchor the latest trailing trends. Over the past few quarters, the company has seen revenue move from €197.4 million in Q4 2024 to €198.2 million in Q1 2025, €211.6 million in Q2 2025, €215.3 million in Q3 2025 and €214.5 million in Q4 2025. Quarterly basic EPS...

ageas (ENXTBR:AGS) has completed the acquisition of the remaining stake in AG Insurance, consolidating full ownership of its Belgian insurance business. The company has issued new and treasury shares to BNP Paribas Cardif, increasing its outstanding share capital and reshaping its shareholder base. ageas is accelerating expansion in India, aiming for a top 10 position through acquisitions and deeper bancassurance partnerships. For investors watching ENXTBR:AGS, these moves come as the share...

Recticel (ENXTBR:RECT) has wrapped up FY 2025 with second half revenue of €319.9 million and basic EPS of €0.19. This is set against a trailing twelve month revenue base of €655.1 million and EPS of €0.09 that reflects the impact of a one off €11.7 million loss on profitability. The company has seen revenue move from €610.2 million in the trailing twelve months to June 2024 to €655.1 million in the latest trailing period, while trailing EPS has shifted from €0.29 to €0.09 as margins have been...

Campine NV's ( EBR:CAMB ) robust earnings report didn't manage to move the market for its stock. Our analysis suggests...

Investors may be wondering if Umicore at around €17.20 is still good value after its recent rebound, or if the easy gains are already behind it. The stock shows mixed returns, with a 7.2% gain over the last month and a 108.2% return over the past year, but declines of 7.5% year to date, 34.4% over three years, and 61.6% over five years. Recent coverage has focused on Umicore as investors reassess materials and specialty chemicals businesses, paying close attention to balance sheet strength...

As European markets face heightened geopolitical tensions and economic uncertainties, traditionally defensive sectors such as utilities and telecoms have shown resilience, with the pan-European STOXX Europe 600 Index recently experiencing a decline. In this environment, dividend stocks can offer a measure of stability and potential income for investors seeking to navigate these challenging times.

UCB (ENXTBR:UCB) is presenting new clinical and real-world data at the American Academy of Neurology Annual Meeting. The updates cover epileptic encephalopathies, prolonged seizures, and generalized myasthenia gravis. Key datasets focus on fenfluramine in Dravet and Lennox Gastaut syndromes and on zilucoplan and rozanolixizumab in myasthenia gravis. Additional findings address patient and caregiver quality of life, healthcare resource use, and treatment patterns. For investors following...